- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05979363
Исследование бортезомиба, леналидомида и дексаметазона (VRd) с последующей терапией BCMA CAR-T у пациентов с первичным плазмоклеточным лейкозом, не подходящих для трансплантации (CAREMM-002)
Safety and Efficiency of VRd-based Regimen Combining BCMA CAR-T for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia. Patients received 3-4 courses of induction therapy with VRD-based regimen followed by infusion of BCMA CAR-T cells. Patients then received 2-3 courses of consolidation therapy, followed by maintenance therapy.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
Контакты и местонахождение
Контакты исследования
- Имя: Gang An, PhD&MD
- Номер телефона: 86-022-23909171
- Электронная почта: angang@ihcams.ac.cn
Места учебы
-
-
-
Tianjin, Китай
- Рекрутинг
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
-
Контакт:
- Gang An, PhD&MD
- Номер телефона: 008613502181109
- Электронная почта: angang@ihcams.ac.cn
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Age ≥ 18 years and ≤ 75 years.
- Participants with documented primary plasma cell leukemia according to IMWG diagnostic criteria (circulating plasma cells ≥5%, determined by morphology on peripheral blood smear; or absolute value of peripheral blood tumorigenic plasma cells exceeds 2×10^9/L).
- Measurable disease, at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or Light chain MM without measurable disease in serum or urine: serum Ig free-light chain (FLC) ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.
- Not considered for high-dose chemotherapy with Autologous Stem Cell Transplant (ASCT) due to: Ineligible due to advanced age (≥65); or Ineligible evaluated by researchers; or Eastern Cooperative Oncology Group Performance Status grade of 3 or 4; or Repeated hematopoietic stem cell mobilization failure; or Deferral of high-dose chemotherapy with ASCT as initial treatment.
- Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
- All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL<2 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT <3 x ULN.; c. Creatinine clearance ≥ 30mL/min (calculated using Cockroft-Gault formula).
- Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC ≥ 1.5 x 109/L, ANC ≥ 1.0 x 109/L, Hb ≥ 70 g/L PLT ≥ 75 x 109/L (if BMPC < 50%) or PLT ≥ 50 x 109/L (if BMPC ≥ 50%).
- Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
- The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.
Exclusion Criteria:
- Documented active amyloidosis.
- Documented with central nervous system (CNS) invasion.
- Prior exposure to any BCMA-targeted therapy or CAR-T therapy.
- Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.
- Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and BCMA-CART cellular products.
- Seropositive for human immunodeficiency virus (HIV)
- Hepatitis B infection
- Hepatitis C infection
- Life expectancy of <6 months
- Women who are pregnant or breastfeeding
- Any active gastrointestinal dysfunction that affects the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that may affect the absorption of the studied treatment medication
- Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
- Received live attenuated vaccine within 4 weeks prior to study treatment.
- According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.
- Necessary medication or supportive therapy is contraindicated with study treatment.
- Any diseases or complications that may interfere with the study.
- Patients are not willing to or cannot comply with study scheme.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: VRD-based Regimen Combined With BCMA CART
VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. BCMA CAR-T products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Participants will receive VRD-based induction, BCMA CAR-T infusion, consolidation, and maintenance. |
Patients receive a single intravenous infusion of one of two BCMA-directed autologous CAR T-cell products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Bortezomib, Lenalidomide and Dexamethasone |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Safety and Tolerability
Временное ограничение: Up to 2 year
|
The incidence of treatment-emergent adverse events (TEAEs) |
Up to 2 year
|
|
MRD-negative rate
Временное ограничение: within 1 week after consolidation treatment
|
achieving MRD-negative, as determined by NGF after consolidation treatment |
within 1 week after consolidation treatment
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Complete response rate (CRR)
Временное ограничение: within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
|
CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria |
within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
|
|
Progression free survival (PFS)
Временное ограничение: Up to 2 year
|
Progression free survival is defined as the time from the date of enrollment to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first |
Up to 2 year
|
|
Overall Survival (OS)
Временное ограничение: Up to 5 year
|
Overall survival is measured from the date of enrollment to the date of the participant's death. |
Up to 5 year
|
|
Duration of Remission(DOR)
Временное ограничение: Up to 2 year
|
Duration of response is defined as the time from the first documented partial response (PR) or better to disease progression or death from any cause, whichever occurs first. |
Up to 2 year
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
The duration of CART cell in vivo
Временное ограничение: Up to 1 year
|
The copies of BCMA-CART DNA in peripheral blood with qPCR method |
Up to 1 year
|
|
Change from Baseline in Physical status assessed by International Myeloma Working Group Comprehensive Geriatric Assessment (IMWG-CGA) scores
Временное ограничение: Baseline up to 5 years
|
The IMWG-CGA was calculated by combining age, activities of daily living (ADL), instrumental ADL (IADL), and Charlson Comorbidity Index (CCI), which ranges from 0 to 5 with higher scores indicating worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by activities of daily living (ADL) scores
Временное ограничение: Baseline up to 5 years
|
The ADL includes 4 items (transfer, bed mobility, toileting, and eating), which range from 0 to 6 scores. A higher score represents worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by instrumental activities of daily living (IADL) scores
Временное ограничение: Baseline up to 5 years
|
The IADL includes 5 items (cooking, cleaning, transportation, laundry, and managing finances), which range from 0 to 8 scores. A higher score represents worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by Charlson Comorbidity Index (CCI)
Временное ограничение: Baseline up to 5 years
|
The CCI estimates the number and the severity of comorbidities, including nineteen diseases with a score varying from 1 to 6 for each of them in accordance to their severity. The score can range from 0 to 37. A higher score represents more severe comorbidities. |
Baseline up to 5 years
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования
- Заболевания иммунной системы
- Новообразования по гистологическому типу
- Гематологические заболевания
- Лимфопролиферативные заболевания
- Иммунопролиферативные заболевания
- Новообразования, Плазматические клетки
- Лейкемия
- Множественная миелома
- Гемики и лимфатические заболевания
- Лейкемия, плазматическая клетка
Другие идентификационные номера исследования
- IIT2023034
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .